⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 19, 2004Science

Organic Chemistry in Drug Discovery

View Full Paper

Ask AI

Bookmark

Share

Key Points

Key points are not available for this paper at this time.

Design

Review

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May inform safer CV drug selection; leaves open prospective validation in clinical cohorts.

Cite This Study

MacCoss et al. (2004) studied this question.

synapsesocial.com/papers/6a816fd74a11a9d2f33390dc https://doi.org/10.1126/science.1096800

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

1Structural Optimization Affording 2-(<i>R</i>)-(1-(<i>R</i>)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(<i>S</i>)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor AntagonistOriginal Research · 1998 · 207 citations
2Drug−Protein Adducts: An Industry Perspective on Minimizing the Potential for Drug Bioactivation in Drug Discovery and DevelopmentOriginal Research · 2003 · 707 citations